Evidence map›Paper›PMID 28885261›Full record

ReviewAdvances in anatomic pathology2017

Epigenetic Alterations in Bone and Soft Tissue Tumors.

John Wojcik, Kumarasen Cooper

Open access · greenAbstract readReview
In one paragraph

Review in Advances in anatomic pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Locally Aggressive Giant Cell Tumor of Bone With Pulmonary Distant Metastasis and Extrapulmonary Seeding in Pregnancy.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

John Wojcik*Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania †University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Kumarasen Cooper
Hospital of the University of Pennsylvania · USUniversity of Pennsylvania · US

Funding

Physician Scientist Training in Clinical OncologyK12CA076931 · NCI · UNIVERSITY OF PENNSYLVANIA · PI STEPHEN Patrick HUNGER, LYNN M. SCHUCHTER · 1997 to 2026
$16.5M
NCI NIH HHS K12 CA076931
6 · The paper itself

Abstract

Human malignancies are driven by heritable alterations that lead to unchecked cellular proliferation, invasive growth and distant spread. Heritable changes can arise from changes in DNA sequence, or, alternatively, through altered gene expression rooted in epigenetic mechanisms. In recent years, high-throughput sequencing of tumor genomes has revealed a central role for mutations in epigenetic regulatory complexes in oncogenic processes. Through interactions with or direct modifications of chromatin, these proteins help control the accessibility of genes, and thus the transcriptional profile of a cell. Dysfunction in these proteins can lead to activation of oncogenic pathways or silencing of tumor suppressors. Although epigenetic regulators are altered across a broad spectrum of human malignancies, they play a particularly central role in tumors of mesenchymal and neuroectodermal origin. This review will focus on recent advances in the understanding of the molecular pathogenesis of a subset of tumors in which alterations in the polycomb family of chromatin modifying complexes, the SWI/SNF family of nucleosome remodelers, and histones play a central role in disease pathogenesis. Although this review will focus predominantly on the molecular mechanisms underlying these tumors, each section will also highlight areas in which an understanding of the molecular pathogenesis of these diseases has led to the adoption of novel immunohistochemical and molecular markers.

Indexed as

Epigenesis, GeneticMutationBiomarkers, TumorBone NeoplasmsChromatin Assembly and DisassemblyGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansNeoplasm ProteinsPhenotypePolycomb Repressive Complex 2Repressor ProteinsSMARCB1 ProteinSoft Tissue NeoplasmsTranscription FactorsBiomarkers, TumorNeoplasm ProteinsPolycomb Repressive Complex 2Repressor ProteinsSMARCB1 ProteinSMARCB1 protein, humansynovial sarcoma X breakpoint proteinsTranscription Factors

Identifiers

PMID28885261
PMCPMC5657591
OpenAlexW2752278913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.